Literature DB >> 8913268

Effect of N-(4-hydroxyphenyl)retinamide on apoptosis in human breast cancer cells.

T T Wang1, J M Phang.   

Abstract

The synthetic retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) has been used in breast cancer prevention and treatment. However, the molecular mechanisms mediating the effects of 4-HPR remain elusive. In the present study, we examined the effects of 4-HPR on components of apoptosis pathway (i.e Bcl-2 and Bax) and apoptotic death in both estrogen receptor-positive and estrogen receptor-negative cell lines. We found that: (1) 4-HPR treatment resulted in decreased Bcl-2 mRNA but not Bax mRNA levels; (2) the effect of 4-HPR on Bcl-2 mRNA level was different from other retinoids; (3) 4-HPR treatment induced apoptosis in both estrogen receptor-positive and -negative cells. Hence, the breast cancer chemopreventive properties of 4-HPR may involve modulation of apoptosis pathways.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8913268     DOI: 10.1016/0304-3835(96)04344-3

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  5 in total

1.  Phase III double-blind, placebo-controlled, prospective randomized trial of adjuvant tamoxifen vs. tamoxifen and fenretinide in postmenopausal women with positive receptors (EB193): an intergroup trial coordinated by the Eastern Cooperative Oncology Group.

Authors:  Ruta D Rao; Melody A Cobleigh; Robert Gray; Mark L Graham; Larry Norton; Silvana Martino; George Thomas Budd; James N Ingle; William C Wood
Journal:  Med Oncol       Date:  2010-09-28       Impact factor: 3.064

2.  Modulation of the malignant phenotype of human prostate cancer cells by N-(4-hydroxyphenyl)retinamide (4-HPR).

Authors:  M M Webber; D Bello-DeOcampo; S Quader; N D Deocampo; W S Metcalfe; R M Sharp
Journal:  Clin Exp Metastasis       Date:  1999-05       Impact factor: 5.150

3.  The effect of transdermal estradiol or oral conjugated oestrogen and fenretinide versus placebo on haemostasis and cardiovascular risk biomarkers in a randomized breast cancer chemoprevention trial.

Authors:  M Lazzeroni; D Macis; A Decensi; S Gandini; M T Sandri; D Serrano; A Guerrieri-Gonzaga; H Johansson; S Mora; C Daldoss; U Omodei; B Bonanni
Journal:  Ecancermedicalscience       Date:  2008-02-06

4.  Growth inhibition of DU-145 prostate cancer cells by a Bcl-2 antisense oligonucleotide is enhanced by N-(2-hydroxyphenyl)all-trans retinamide.

Authors:  M J Campbell; M Dawson; H P Koeffler
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

5.  Inhibition of aromatase activity and expression in MCF-7 cells by the chemopreventive retinoid N-(4-hydroxy-phenyl)-retinamide.

Authors:  H P Ciolino; T T Wang; N Sathyamoorthy
Journal:  Br J Cancer       Date:  2000-08       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.